Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 April 2021Website:
http://biomeafusion.comNext earnings report:
31 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:51:38 GMTDividend
Analysts recommendations
Institutional Ownership
BMEA Latest News
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biomea Fusion, Inc. (“Biomea” or the “Company”) (NASDAQ: BMEA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public.
LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.
NEW YORK , July 1, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public. So what: If you purchased Biomea Fusion securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biomea Fusion, Inc. (“Biomea” or the “Company”) (NASDAQ: BMEA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biomea Fusion, Inc.. ("Biomea" or "the Company") (NASDAQ:BMEA) violations of the securities laws.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public.
What type of business is Biomea Fusion?
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
What sector is Biomea Fusion in?
Biomea Fusion is in the Healthcare sector
What industry is Biomea Fusion in?
Biomea Fusion is in the Biotechnology industry
What country is Biomea Fusion from?
Biomea Fusion is headquartered in United States
When did Biomea Fusion go public?
Biomea Fusion initial public offering (IPO) was on 16 April 2021
What is Biomea Fusion website?
https://biomeafusion.com
Is Biomea Fusion in the S&P 500?
No, Biomea Fusion is not included in the S&P 500 index
Is Biomea Fusion in the NASDAQ 100?
No, Biomea Fusion is not included in the NASDAQ 100 index
Is Biomea Fusion in the Dow Jones?
No, Biomea Fusion is not included in the Dow Jones index
When does Biomea Fusion report earnings?
The next expected earnings date for Biomea Fusion is 31 July 2024